Inotrem’s COVID-19 Phase IIa Clinical Trial declared “National Priority Research” by the French government’s Clinical Trial Council
December 24, 2020
Paris, December 24. 2020. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announces today that its Phase IIa
